About Dr. Mark Lebwohl MD

Dr. Mark Lebwohl graduated summa cum laude from Columbia College in 1974 and graduated from Harvard Medical School in 1978.  He completed residencies in internal medicine and dermatology, both at Mount Sinai.

Dr. Lebwohl has been practicing dermatology since 1983.  He is professor and chairman of the Department of Dermatology at The Mount Sinai School of Medicine.  Dr. Lebwohl has served as president of the New York Dermatological Society, the Manhattan Dermatologic Society, and the New York State Society of Dermatology, and as chairman of the Dermatology Section of the New York Academy of Medicine.

Dr. Lebwohl has served as chairman of the Psoriasis Task Force of the American Academy of Dermatology, and has directed the AAD’s annual Psoriasis Symposium, Diagnostic Update Symposium and Therapeutics Symposium.  He was a member of the Scientific Assembly Council, and chaired Academy 2001 in California and the AAD annual meeting in Washington, D.C. in 2004.

Mark Lebwohl, M.D. is chairman of the Medical Board of the National Psoriasis Foundation.  He is the founding editor of Psoriasis Forum as well as medical editor of the bulletin of the National Psoriasis Foundation, Psoriasis Advance.

He is on the editorial board of the Journal of the American Academy of Dermatology and is editor of the Dermatology Section of Scientific American Medicine, now called ACP Medicine.

Mark Lebwohl, M.D. has chaired numerous symposia and has written or edited several books including the first atlas devoted entirely to cutaneous manifestations of systemic disease, and the leading book on dermatologic therapy, Treatment of Skin Disease. The second edition of The Skin and Systemic Disease has been published in English and in French, and both English and Portuguese versions of Treatment of Skin Disease have been published. Other books include Difficult Diagnoses in Dermatology and Psoriasis.  Dr. Lebwohl has authored or co-authored over 400 publications including articles, chapters and abstracts. Dr. Lebwohl is actively involved in clinical trials of many new dermatologic treatments.